Eddy Anglade, Tenpoint Therapeutics CEO
Tenpoint Therapeutics launches with $70M to restore vision with stem cell therapies and ‘reprogramming’ medicines
Although numerous biotech companies are developing gene therapies to correct eyesight, these approaches largely require the affected cells to remain intact — while many forms of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
